Introduction The landscape of modern drug development is undergoing a profound transformation, largely driven by the imperative to increase efficiency and precision in early-stage clinical trials. Traditional methodologies for identifying patient responses and therapeutic targets often relied on sequential testing, which proved both time-consuming and economically demanding. Says Andrew Hillman, today, the integration of advanced molecular […]